Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Clinical development may resume, with further FDA engagement and alignment on the Phase 3 trial design still anticipated.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aardvark Therapeutics (Nasdaq: AARD) announced that the FDA lifted the clinical hold on ARD-101 for excessive hunger in Prader-Willi syndrome.
No cardiac events were observed in a recently completed study in healthy volunteers at 200 mg and 400 mg twice daily. Dosing in HERO and its open-label extension had been voluntarily paused following reversible electrocardiogram changes in a separate healthy-volunteer study. Aardvark plans to resume clinical development following further FDA engagement and alignment on the Phase 3 trial design. The company will review available exploratory data from the terminated HERO and extension trials on October 23, 2026, at 8:00 a.m. ET.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA lifted the clinical hold on ARD-101 for hyperphagia in Prader-Willi syndrome.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Aardvark plans to resume clinical development of ARD-101 in patients with Prader-Willi syndrome.
- Minor pointNo cardiac events were observed in the completed healthy-volunteer ECG study at 200 mg and 400 mg twice daily.
Negative
- Major pointHERO and its open-label extension were terminated; available data have been unblinded.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Further FDA engagement and alignment on Phase 3 trial design precede the planned development resumption.
- Moderate pointReversible ECG changes in a separate healthy-volunteer study prompted the February 27, 2026, voluntary dosing pause.
Details
Market move: AARD +22.03% vs previous close. ARD-101 clinical hold lift
On Oct 22, the day this news came out, the latest delayed price for AARD is 22.03% above the previous close. Argus tracked a peak move of +17.9% during the session. Argus tracked a trough of -11.2% from its starting point during tracking. Our momentum scanner has recorded 17 alerts for this stock so far that day. The latest delayed price is $4.82. Relative volume is exceptionally heavy at 13.3x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Doses with no cardiac events observed
- 200 mg and 400 mg twice daily
- Completed ECG study in healthy volunteers
Previous Clinical trial Reports
-
Company paused HERO/OLE dosing after reversible cardiac observations in healthy volunteers.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
clinical hold regulatory
investigational new drug application regulatory
open-label extension medical
electrocardiogram medical
cardiac sodium channel medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume
Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October 23, 2026, at 8:00 a.m. EST
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug application for ARD-101 for the treatment of hyperphagia in PWS.
“We are pleased that the FDA has lifted the clinical hold on ARD-101, allowing us to continue advancing our clinical development program,” said Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark. “With strong alignment and collaboration with the FDA, we completed the work necessary to allow for the resumption of clinical studies. People living with PWS and their families continue to face profound unmet need, and we look forward to working with the FDA as we advance ARD-101.”
On February 27, 2026, Aardvark voluntarily paused dosing in the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and its open-label extension (OLE) trial following reversible electrocardiogram (ECG) changes observed during routine safety monitoring in a separate study in healthy volunteers. In May 2026, the FDA placed a clinical hold on the HERO trial and OLE trial. In alignment with the FDA, the Company conducted a thorough ECG study in additional healthy volunteers and an in vitro cardiac sodium channel (NaV1.5) study. No cardiac events were observed in the recently completed ECG study at ARD-101 doses of 200 mg and 400 mg twice daily.
Aardvark plans to resume clinical development of ARD-101 in patients with PWS following additional anticipated engagement and alignment with the FDA on the Phase 3 trial design. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data.
Conference Call and Webcast
The Company will host a live conference call and webcast for investors to discuss data from the terminated HERO and OLE trials tomorrow, October 23, 2026, at 8:00 AM ET. To access the live conference call, participants may register here. To access the live webcast and subsequent archived recording of this event, please visit the Investors section of Aardvark’s website.
About ARD-101
ARD-101 is an oral, small-molecule therapeutic designed to stimulate the release of gut-peptide hormones through activation of bitter taste receptors. ARD-101 is being developed as a treatment for hyperphagia associated with Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable hunger.
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. For more information, visit www.aardvarktherapeutics.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning: Aardvark’s business strategy, product candidates, the path forward for ARD-101, including the anticipated resumption of the clinical development of ARD-101 and any further engagement and alignment with the FDA prior to such resumption, as well as plans and objectives of management for future operations. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the risk that the FDA may not agree with Aardvark’s proposed Phase 3 program or may require additional studies; limitations in interpreting data from the HERO trial and its OLE trial, which were terminated early and were not powered to assess efficacy; the risk of unfavorable clinical trial results; the risk that results from earlier clinical trials and preclinical studies may not necessarily be predictive of future results; the risk that Aardvark may use its capital resources sooner than expected; and other risks and uncertainties, including the factors described under the “Risk Factors” section of Aardvark’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 11, 2026. When evaluating Aardvark’s business and prospects, careful consideration should be given to these risks and uncertainties. Any forward-looking statements contained in this press release are based on the current expectations of Aardvark’s management team and speak only as of the date hereof, and Aardvark specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.
Investor and Media Contact
Argot Partners
(212) 600-1902
Aardvark@Argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the FDA lifting Aardvark's ARD-101 clinical hold mean?
Clinical development of ARD-101 for hyperphagia in Prader-Willi syndrome may resume. Aardvark plans to resume development following additional anticipated engagement and alignment with the FDA on the Phase 3 trial design.
What cardiac safety testing did Aardvark complete for ARD-101?
Aardvark conducted an ECG study in additional healthy volunteers and a laboratory study of the cardiac sodium channel NaV1.5, in alignment with the FDA. No cardiac events were observed in the recently completed ECG study at ARD-101 doses of 200 mg and 400 mg twice daily.